BSN medical

EBITDA: EUR 201 million in 2015
Number of Employees: 6,100
Sales: EUR 861 million in 2015

BSN medical is a leading global medical device company that develops, manufactures and markets wound care, compression therapy and non-invasive orthopaedic products mainly to hospitals, pharmacies and sanitary shops.

BSN medical has production facilities in Germany, France, Colombia, Brazil, India, Mexico, Pakistan, South Africa and New Zealand, operating globally through its own sales & distribution network, joint ventures and distribution agents.

The Wound Care & Vascular segment includes the Wound Care business which comprises both Acute and Advanced Wound Care products as well as the Compression Therapy business which focuses on ready-to-wear and custom-made compression garments, covering phlebology and lymphology indications.

In Orthopaedics, BSN offers a comprehensive range of products for fracture management, physiotherapy and orthopedic soft goods. BSN owns and manufactures several established brands such as Leukoplast®, Leukomed®, Gypsona®, Orthoglass®, JOBST®, Radiante®, Delta-cast®, Actimove® and Tricodur®.

BSN was established as a joint venture between Beiersdorf AG and Smith & Nephew plc in 2001.

To BSN medical

Market trends and drivers

BSN operates in a market that is driven by an ageing population and increasing life expectancy in combination with rising levels of obesity and diabetes, but also a trend towards a more active lifestyle. Established market growth is estimated at around 3% per year until 2017 and emerging market growth at approximately 6% year.

Investment potential

The strong underlying growth potential and BSN's leading market position in key product areas were the key drivers behind EQT's investment in the company.

The development plan includes geographical expansion into markets such as Brazil and China and a strengthening of the sales organization in existing markets. Local manufacturing in Asia is to be set up. Focusing resources on certain geographies and sub-segments where potential is looking most promising is included in the development plan. Further, both smaller and larger acquisitions may be considered to add geographies and new products.